1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6CE04307E18F4876000258546004D2CC6
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/navigating-kpi-performance-measurement-challenges-during-global-covid-19-pandemic?opendocument
18
19opendocument
203.237.15.145
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




» Products & Services » » Human Resources » Employee Staffing and Performance Measures

Navigating KPI and Performance Measurement Challenges During the Global COVID-19 Pandemic

ID: CM-2


Features:

9 Info Graphics

9 Data Graphics

50+ Metrics

22 Narratives


Pages: 28


Published: 2020


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
In response to the COVID-19 pandemic outbreak, organizations have moved quickly to a virtual set-up to mitigate work disruptions. While this situation demands improved dedication from employees to maintain business stability, many organizations are in a fix as how to measure the performance of their employees during the COVID-19 pandemic.


Best Practices, LLC conducted this benchmarking research to find out how life science companies are changing key performance indicators (KPIs) during the COVID-19 pandemic.

This new report examines critical adjustments being made in KPIs and performance measurement, measurement period, authority, and duration in order to accurately monitor and manage performance during the pandemic. The report also highlights the top challenges being encountered around performance measurement and suggestions from industry peers for improved assessment during COVID-related business disruption.


Industries Profiled:
Biotech; Pharmaceutical; Biopharmaceutical; Health Care; Communications; Medical Device; Research; Clinical Research; Laboratories; Science


Companies Profiled:
Allergan; Almirall; Arena Pharmaceuticals; Astellas; Braeburn; Cipla; Daiichi Sankyo; Eagle Pharmaceuticals; EMD Serono; Grifols; Grünenthal; Guerbet; Horizon Therapeutics; LEO Pharma; Lupin; Melinta Therapeutics; Inc; Merck; Milestone Pharmaceuticals; NexGen Healthcare Communications; Novartis; Pfizer; Roche; Sarah Cannon; Sanofi Genzyme; Sanofi; Thermo Fisher Scientific; Think Surgical; Inc.; Takeda Pharmaceuticals; XACT Robotics

Study Snapshot

Best Practices, LLC engaged 40 executives from 29 life science companies in this research through a benchmarking survey. About 80% of the participants serve at the director level or above, with 88% of respondents from pharma and the rest from medical device and diagnostic companies.

Key topics covered in this report include:

  • Performance measurement changes during the pandemic
  • Changes in KPIs and reasons for the changes
  • Change in measurement period of KPIs and reasons for the change
  • KPI change authority and duration
  • Struggles in KPI standardization during the pandemic
  • Suggestions in adapting changes in KPI during the pandemic

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Companies adopting softer metrics: With about half of companies changing their KPIs already, many are opting for softer measurements as doctors and others in healthcare are unavailable at this point in the crisis.

  • Current KPI situation will change as crisis lessens: Constant evaluation of metrics should be expected. Once the pandemic crisis ebbs, management will seek to re-assess KPIs more fully, according to 60% of respondents.

  • Evolving metrics coming for medical affairs and sales: Besides the elimination of F2F measurements, some companies are cutting virtual KPIs as reaching HCPs remains difficult. There are shifts to learning goals and project-based KPIs in both functions – things within an individual’s control.
Table of Contents

Sr. No.
Topic
Slide No.
I.
Overviewpgs. 3-6
Universe of Learningpg. 4
Key Actionspgs. 5-6
II.
Performance Measurement Changespgs. 7-10
III.
Changes in KPIspgs. 11-16
IV.
Change in Measurement Period of KPIspgs. 17-18
V.
Changes in Authority and Durationpgs. 19-21
VI.
Struggles and Suggestions in KPI Changepgs. 22-24
VII.
Participant Demographicspgs. 25-27
VIII.
About Best Practices, LLCpg. 28

    List of Charts & Exhibits

    I. Overview

    • Benchmark study partners
    • Key signal readout from how companies will approach KPI changes during the COVID-19 pandemic
    • Words of wisdom from industry peers

    II. Performance Measurement Changes

    • Expected percentage change in overall KPIs over the course of the pandemic
    • Changes in performance measurement to better track the value of external engagements, considering the constraints around travel and visitation in the short term
    • Implementation of changes to performance tracking

    III. Changes in KPIs

    • Changes in KPIs since the emergence of the global pandemic, reasoning behind the described KPI changes
    • Interview narratives around concerns regarding intruding on overburdened physicians in the short-term
    • Consider a change in focus during pandemic
    • Possible changes in KPIs for Medical Affairs executives
    • Possible changes in KPIs for commercial/sales executives

    IV. Change in Measurement Period of KPIs

    • Change in measurement period of KPIs since the emergence of the global pandemic, reasoning behind the same

    V. Changes in Authority and Duration

    • Authority level of the person directing the changes to the group’s KPIs to improve their utility during the global pandemic
    • Approach to dealing with KPI changes after the global pandemic is over

    VI. Struggles and Suggestions in KPI Change

    • Struggles experienced or expected to experience around performance measurement during the global pandemic
    • Suggestions for best adapting KPIs and other measurements during the global pandemic to better reflect performance